An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G. Wysham; Donald R. Sullivan; Gopal Allada

doi:10.1378/chest.12-1604

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Nicholas G. Wysham, Donald R. Sullivan, Gopal Allada

Research output: Contribution to journal › Article › peer-review

96 Scopus citations

Abstract

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

Original language	English (US)
Pages (from-to)	1478-1479
Number of pages	2
Journal	CHEST
Volume	143
Issue number	5
DOIs	https://doi.org/10.1378/chest.12-1604
State	Published - May 2013

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.12-1604

Cite this

@article{d452a8188c2a49219bb4d590095306b1,

title = "An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor",

abstract = "We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.",

author = "Wysham, {Nicholas G.} and Sullivan, {Donald R.} and Gopal Allada",

year = "2013",

month = may,

doi = "10.1378/chest.12-1604",

language = "English (US)",

volume = "143",

pages = "1478--1479",

journal = "CHEST",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "5",

}

TY - JOUR

T1 - An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

AU - Wysham, Nicholas G.

AU - Sullivan, Donald R.

AU - Allada, Gopal

PY - 2013/5

Y1 - 2013/5

N2 - We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

AB - We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

UR - http://www.scopus.com/inward/record.url?scp=84877618100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877618100&partnerID=8YFLogxK

U2 - 10.1378/chest.12-1604

DO - 10.1378/chest.12-1604

M3 - Article

C2 - 23648912

AN - SCOPUS:84877618100

SN - 0012-3692

VL - 143

SP - 1478

EP - 1479

JO - CHEST

JF - CHEST

IS - 5

ER -

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this